Can COVID-19 Increase Platelet in Adult Immune Thrombocytopenia During the TPO-RA Administration? A Real-World Observational Study

References

• Franchini M, Veneri D, Lippi G. Thrombocytopenia and infections. Expert Rev Hematol. 2017;10(1):99–106. doi:10.1080/17474086.2017.1271319
   PubMed Web of Science ®Google Scholar
• Zufferey A, Kapur R, Semple JW. Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP). J Clin Med. 2017;6(2):16. doi:10.3390/jcm6020016
   PubMed Web of Science ®Google Scholar
• Bomhof G, Mutsaers P, Leebeek FWG, et al. COVID-19-associated immune thrombocytopenia. Br J Haematol. 2020;190(2):e61–e64. doi:10.1111/bjh.16850
   PubMed Web of Science ®Google Scholar
• Auteri G, Paglia S, Mazzoni C, et al. Immune thrombocytopenia onset and relapse during the COVID-19 pandemic. A monocenter study. Mediterr J Hematol Infect Dis. 2023;15(1):e2023029. doi:10.4084/mjhid.2023.029
   PubMed Web of Science ®Google Scholar
• Boehm BA, Packer CD. Persistent relapsing immune thrombocytopenia following COVID-19 infection. Cureus. 2022;14(7):e27133. doi:10.7759/cureus.27133
   PubMed Web of Science ®Google Scholar
• Alharbi MG, Alanazi N, Yousef A, et al. COVID-19 associated with immune thrombocytopenia: a systematic review and meta-analysis. Expert Rev Hematol. 2022;15(2):157–166. doi:10.1080/17474086.2022.2029699
   PubMed Web of Science ®Google Scholar
• Rampotas A, Watson E, Burton K, et al. A real-world study of immune thrombocytopenia management during the COVID-19 pandemic in the UK. Br J Haematol. 2022;196(2):351–355. doi:10.1111/bjh.17804
   PubMed Web of Science ®Google Scholar
• Murt A, Eskazan AE, Yılmaz U, et al. COVID-19 presenting with immune thrombocytopenia: a case report and review of the literature. J Med Virol. 2021;93(1):43–45. doi:10.1002/jmv.26138
   PubMed Web of Science ®Google Scholar
• Singh S, Sharma R, Singh J, et al. Thrombocytopenia in COVID-19: focused summary of current understanding of mechanisms and clinical implications. J Pediatr Hematol Oncol. 2021;43(7):243–248. doi:10.1097/MPH.0000000000002264
   PubMed Web of Science ®Google Scholar
• de la Cruz-Benito B, Rivas-Pollmar MI, Álvarez Román MT, et al. Paradoxical effect of SARS-CoV-2 infection in patients with immune thrombocytopenia. Br J Haematol. 2021;192(6):973–977. doi:10.1111/bjh.17077
   PubMed Web of Science ®Google Scholar
• Pantic N, Suvajdzic-Vukovic N, Virijevic M, et al. Coronavirus disease 2019 in patients with chronic immune thrombocytopenia on thrombopoietin receptor agonists: new perspectives and old challenges. Blood Coagul Fibrinolysis. 2022;33(1):51–55. doi:10.1097/mbc.0000000000001109
   PubMed Web of Science ®Google Scholar
• Wang Z, Cheng X, Wang N, et al. Transient increase in platelet counts associated with COVID-19 infection during TPO-RA as the second-line treatment in children with ITP. Br J Haematol. 2023;203(3):384–388. doi:10.1111/bjh.19040
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–2393. doi:10.1182/blood-2008-07-162503
   PubMed Web of Science ®Google Scholar
• Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–3866. doi:10.1182/bloodadvances.2019000966
   PubMed Web of Science ®Google Scholar
• Chen LYC, Hoiland RL, Stukas S, et al. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome. Eur Respir J. 2020;56(4):2003006. doi:10.1183/13993003.03006-2020
   PubMed Web of Science ®Google Scholar
• Behrens K, Alexander WS. Cytokine control of megakaryopoiesis. Growth Factors. 2018;36(3–4):89–103. doi:10.1080/08977194.2018.1498487
   PubMed Web of Science ®Google Scholar
• Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366(7):610–618. doi:10.1056/NEJMoa1110352
   PubMed Web of Science ®Google Scholar
• Zhang S, Asquith B, Szydlo R, et al. Peripheral T cell lymphopenia in COVID-19: potential mechanisms and impact. Immunother Adv. 2021;1(1):ltab015. doi:10.1093/immadv/ltab015
   PubMedGoogle Scholar
• Nørgaard M. Thrombosis in patients with primary chronic immune thrombocytopenia. Thromb Res. 2012;130(Suppl 1):S74–S75. doi:10.1016/j.thromres.2012.08.282
   PubMedGoogle Scholar
• Langeberg WJ, Schoonen WM, Eisen M, et al. Thromboembolism in patients with immune thrombocytopenia (ITP): a meta-analysis of observational studies. Int J Hematol. 2016;103(6):655–664. doi:10.1007/s12185-016-1974-6
   PubMed Web of Science ®Google Scholar
• Mroueh A, Fakih W, Carmona A, et al. COVID-19 promotes endothelial dysfunction and thrombogenicity: role of proinflammatory cytokines/SGLT2 prooxidant pathway. J Thromb Haemost. 2023;22(1):286–299. doi:10.1016/j.jtha.2023.09.022
   PubMed Web of Science ®Google Scholar
• Iba T, Connors JM, Levy JH. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm Res. 2020;69(12):1181–1189. doi:10.1007/s00011-020-01401-6
   PubMed Web of Science ®Google Scholar
• Babkina AS, Yadgarov MY, Volkov AV, et al. Spectrum of thrombotic complications in fatal cases of COVID-19: focus on pulmonary artery thrombosis in situ. Viruses. 2023;15(8):1681. doi:10.3390/v15081681
   PubMed Web of Science ®Google Scholar
• Soudet S, Basille D, Carette H, et al. Cardiovascular and venous thromboembolic events after hospital discharge for COVID-19: a prospective single center study. Angiology. 2023:33197231196175. doi:10.1177/00033197231196175
   PubMed Web of Science ®Google Scholar
• Honkanen M, Sirkeoja S, Viskari H, et al. Risk of venous thromboembolism in COVID-19 infection. Intern Med J. 2023;53(8):1478–1480. doi:10.1111/imj.16145
   PubMed Web of Science ®Google Scholar
• Glober N, Stewart L, Seo J, et al. Incidence and characteristics of arterial thromboemboli in patients with COVID-19. Thromb J. 2021;19(1):104. doi:10.1186/s12959-021-00357-9
   PubMed Web of Science ®Google Scholar
• Gonzalez-Urquijo M, Gonzalez-Rayas JM, Castro-Varela A, et al. Unexpected arterial thrombosis and acute limb ischemia in COVID-19 patients. Results from the Ibero-Latin American acute arterial thrombosis registry in COVID-19: (ARTICO-19). Vascular. 2022;30(6):1107–1114. doi:10.1177/17085381211052033
   PubMed Web of Science ®Google Scholar
• Tayebi P, Zavareh MSH, Tayyebi G, et al. Extensive acute lower extremity arterial thrombosis: a major thrombus formation caused by COVID-19. Vasc Specialist Int. 2021;37:36. doi:10.5758/vsi.210039
   PubMedGoogle Scholar
• Imbach P, Crowther M. Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N Engl J Med. 2011;365(8):734–741. doi:10.1056/NEJMct1014202
   PubMed Web of Science ®Google Scholar
• Tjepkema M, Amini S, Schipperus M. Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2022;171:103581. doi:10.1016/j.critrevonc.2022.103581
   PubMed Web of Science ®Google Scholar
• Garabet L, Ghanima W, Monceyron Jonassen C, et al. Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia. Platelets. 2019;30(2):206–212. doi:10.1080/09537104.2017.1394451
   PubMed Web of Science ®Google Scholar